CPX-351 in Clinical Practice For AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP, comments on her experience with CPX-351 in clinical practice and the potential to combine CPX-351 with targeted agents for AML.

EP: 1.Role of First Generation FLT3 Inhibitors in AML

EP: 2.Role of Second Generation FLT3 Inhibitors in AML

EP: 3.Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 4.Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 5.Role of Venetoclax in Treatment of AML

EP: 6.Part 1: Practical Considerations For Venetoclax in AML

EP: 7.Part 2: Practical Considerations For Venetoclax in AML

EP: 8.5-Year Follow-Up Data For CPX-351 in AML

Now Viewing

CPX-351 in Clinical Practice For AML

EP: 1.Role of First Generation FLT3 Inhibitors in AML

EP: 2.Role of Second Generation FLT3 Inhibitors in AML

EP: 3.Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 4.Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

EP: 5.Role of Venetoclax in Treatment of AML

EP: 6.Part 1: Practical Considerations For Venetoclax in AML

EP: 7.Part 2: Practical Considerations For Venetoclax in AML

EP: 8.5-Year Follow-Up Data For CPX-351 in AML

EP: 9.CPX-351 in Clinical Practice For AML